Company intelligence / Profile preview

Bitterroot Welding

California, United Statesbitterrootweld.com ↗

Ownership: Private
Development stage: Other

Overview

Bitterroot Bio develops immunotherapies for cardiovascular disease by targeting immune system dysfunction underlying atherosclerosis and vascular inflammation. Its lead program, BRB‑002, targets the CD47/SIRPα pathway to promote efferocytosis and reduce plaque buildup. The company has completed preclinical efficacy/safety studies in animal models and plans to enter clinical trials soon. Series A funding ($145M) will support advancement through Phase 1/2a trials.

Therapeutic areas: Cardiovascular
Modalities: Protein therapyBiologic
Industry: Biotech

Partnerships

ARCH Venture PartnersDeerfield ManagementGV (Google Ventures)Koch Disruptive TechnologiesAlexandria Venture Investments

Beyond the preview

Go deeper on Bitterroot Welding.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bitterroot Welding.

Explore the full profile